Comparing Investment Prospects of Heartflow and Omeros
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: NASDAQ.COM
- Heartflow Revenue Growth: In FY 2025, Heartflow reported approximately $176 million in revenue, a 40% increase year-over-year, despite a net loss of $116.8 million, highlighting its heavy reliance on the core FFR CT Analysis product and the need to monitor potential policy impacts on revenue.
- Omeros Commercial Transition: Omeros launched its first commercial product, Yartemlea, at the end of 2025, and although it did not generate revenue that year, it achieved $9.89 million in sales in Q1 2026, indicating strong market interest and potential for profitability in the future.
- Market Competition Risks: Heartflow faces significant risks from government policy changes that could reduce reimbursements for its core product by 15%, along with ongoing intellectual property litigation that may affect investor sentiment, necessitating careful evaluation of its market position.
- Omeros Dependency: Omeros is highly dependent on the commercial success of Yartemlea and its partnership with Novo Nordisk, making any setbacks in the product launch potentially devastating to its stock, while the company continues to rely on capital markets to sustain operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HTFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 26.150
Low
35.00
Averages
38.60
High
40.00
Current: 26.150
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choice Between Heartflow and Omeros in 2026
- Revenue Growth Comparison: Heartflow achieved approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite a net loss of $116.8 million, indicating strong market demand for its core FFR CT analysis product; however, its heavy reliance on a single product poses significant risks.
- Omeros Commercialization Progress: Following the approval of Yartemlea at the end of 2025, Omeros did not book any revenue that year but expects $9.89 million in sales for Q1 2026, reflecting strong market interest in the treatment, with management anticipating significant revenue growth in the future.
- Cash Flow Status: Heartflow reported nearly negative $59 million in free cash flow for 2025, highlighting the high costs associated with its technology commercialization, while Omeros faced a negative $116.2 million in free cash flow, indicating financial pressure in drug development and marketing.
- Market Outlook Analysis: While Heartflow's application of AI technology is promising, Omeros's transition to a commercial entity and its partnership with Novo Nordisk may provide more stable revenue streams, with analysts projecting profitability for Omeros by 2028, suggesting its long-term investment value.
See More
Comparing Investment Prospects of Heartflow and Omeros
- Heartflow Revenue Growth: In FY 2025, Heartflow reported approximately $176 million in revenue, a 40% increase year-over-year, despite a net loss of $116.8 million, highlighting its heavy reliance on the core FFR CT Analysis product and the need to monitor potential policy impacts on revenue.
- Omeros Commercial Transition: Omeros launched its first commercial product, Yartemlea, at the end of 2025, and although it did not generate revenue that year, it achieved $9.89 million in sales in Q1 2026, indicating strong market interest and potential for profitability in the future.
- Market Competition Risks: Heartflow faces significant risks from government policy changes that could reduce reimbursements for its core product by 15%, along with ongoing intellectual property litigation that may affect investor sentiment, necessitating careful evaluation of its market position.
- Omeros Dependency: Omeros is highly dependent on the commercial success of Yartemlea and its partnership with Novo Nordisk, making any setbacks in the product launch potentially devastating to its stock, while the company continues to rely on capital markets to sustain operations.
See More
Investment Comparison: Heartflow vs Iovance
- Market Positioning: Heartflow focuses on non-invasive AI diagnostics for heart disease, maintaining over 1,450 accounts, with FY 2025 revenue reaching $176 million, a 40% increase, yet reporting a net loss of $116.8 million, indicating high business risk.
- Product Dependency: Heartflow's FFR CT Analysis product generates 98% of its revenue, creating significant concentration risk, while also facing a U.S. Department of Justice investigation and a potential 15% reduction in Medicare reimbursements in 2026.
- Growth Potential of Iovance: Iovance Biotherapeutics specializes in personalized tumor-infiltrating lymphocyte therapies, reporting FY 2025 revenue of $263.5 million, a 60.6% growth, despite a net loss of $391 million, with expectations for its products to become blockbusters in the pharmaceutical industry.
- Financial Health Status: Iovance's debt-to-equity ratio stands at approximately 0.1, indicating a relatively healthy financial structure; however, its negative free cash flow of $336.2 million reflects the high capital demands of personalized cell therapy manufacturing, potentially impacting long-term growth capacity.
See More
Evaluating AI and Personalized Cell Therapy Investment Opportunities
- Heartflow Financial Performance: Heartflow reported a revenue of $176 million for FY 2025, reflecting a 40% year-over-year increase despite a net loss of $116.8 million, with its core FFR CT Analysis product generating 98% of revenue, indicating strong market demand and growth potential.
- Iovance Revenue Growth: Iovance achieved a revenue of $263.5 million in FY 2025, marking a 60.6% increase year-over-year, although it recorded a net loss of approximately $391 million; the successful commercialization of its primary products Amtagvi and Proleukin highlights its strong potential in cancer treatment.
- Risk Analysis: Heartflow faces significant concentration risk due to reliance on a single product, alongside scrutiny from a U.S. Department of Justice investigation and potential Medicare reimbursement cuts, while Iovance contends with a $2.9 billion accumulated deficit and risks associated with its complex manufacturing processes.
- Valuation Comparison: Neither company is expected to be profitable in 2026, with Heartflow's price-to-sales ratio at 13.8 and Iovance at 5.3, suggesting that Iovance may offer a more attractive risk-adjusted opportunity for investors based on its lower valuation metrics.
See More
Investment Choices Between HeartFlow and NovoCure: Diagnostics vs. Therapeutics
- HeartFlow's Diagnostic Technology: HeartFlow employs AI for non-invasive diagnosis of coronary artery disease, achieving approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite reporting a net loss of $116.8 million, highlighting a tension between market expansion potential and profitability.
- Cancer Treatment Innovation: NovoCure's Tumor Treating Fields therapy generated about $655.4 million in revenue for FY 2025, an 8.3% increase, yet it also faced a net loss of nearly $136.2 million, indicating ongoing pressure from significant investments in its clinical pipeline.
- Risks and Challenges: HeartFlow's revenue is heavily concentrated, with 98% coming from its core diagnostic tool, and it is currently under a Civil Investigative Demand from the DOJ and facing patent litigation, which could impact future revenues; meanwhile, NovoCure's reliance on its Optune products exposes it to regulatory risks and collaboration risks with Zai Lab.
- Market Outlook Comparison: Although neither company is profitable, NovoCure's projected revenue of $704 million for FY 2026 significantly surpasses HeartFlow's $230 million, and its lower price-to-sales ratio presents a relative bargain, making NovoCure a more attractive option for long-term investors.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
Investment Choice Between Heartflow and Omeros in 2026
- Revenue Growth Comparison: Heartflow achieved approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite a net loss of $116.8 million, indicating strong market demand for its core FFR CT analysis product; however, its heavy reliance on a single product poses significant risks.
- Omeros Commercialization Progress: Following the approval of Yartemlea at the end of 2025, Omeros did not book any revenue that year but expects $9.89 million in sales for Q1 2026, reflecting strong market interest in the treatment, with management anticipating significant revenue growth in the future.
- Cash Flow Status: Heartflow reported nearly negative $59 million in free cash flow for 2025, highlighting the high costs associated with its technology commercialization, while Omeros faced a negative $116.2 million in free cash flow, indicating financial pressure in drug development and marketing.
- Market Outlook Analysis: While Heartflow's application of AI technology is promising, Omeros's transition to a commercial entity and its partnership with Novo Nordisk may provide more stable revenue streams, with analysts projecting profitability for Omeros by 2028, suggesting its long-term investment value.
See More
Comparing Investment Prospects of Heartflow and Omeros
- Heartflow Revenue Growth: In FY 2025, Heartflow reported approximately $176 million in revenue, a 40% increase year-over-year, despite a net loss of $116.8 million, highlighting its heavy reliance on the core FFR CT Analysis product and the need to monitor potential policy impacts on revenue.
- Omeros Commercial Transition: Omeros launched its first commercial product, Yartemlea, at the end of 2025, and although it did not generate revenue that year, it achieved $9.89 million in sales in Q1 2026, indicating strong market interest and potential for profitability in the future.
- Market Competition Risks: Heartflow faces significant risks from government policy changes that could reduce reimbursements for its core product by 15%, along with ongoing intellectual property litigation that may affect investor sentiment, necessitating careful evaluation of its market position.
- Omeros Dependency: Omeros is highly dependent on the commercial success of Yartemlea and its partnership with Novo Nordisk, making any setbacks in the product launch potentially devastating to its stock, while the company continues to rely on capital markets to sustain operations.
See More
Investment Comparison: Heartflow vs Iovance
- Market Positioning: Heartflow focuses on non-invasive AI diagnostics for heart disease, maintaining over 1,450 accounts, with FY 2025 revenue reaching $176 million, a 40% increase, yet reporting a net loss of $116.8 million, indicating high business risk.
- Product Dependency: Heartflow's FFR CT Analysis product generates 98% of its revenue, creating significant concentration risk, while also facing a U.S. Department of Justice investigation and a potential 15% reduction in Medicare reimbursements in 2026.
- Growth Potential of Iovance: Iovance Biotherapeutics specializes in personalized tumor-infiltrating lymphocyte therapies, reporting FY 2025 revenue of $263.5 million, a 60.6% growth, despite a net loss of $391 million, with expectations for its products to become blockbusters in the pharmaceutical industry.
- Financial Health Status: Iovance's debt-to-equity ratio stands at approximately 0.1, indicating a relatively healthy financial structure; however, its negative free cash flow of $336.2 million reflects the high capital demands of personalized cell therapy manufacturing, potentially impacting long-term growth capacity.
See More
Evaluating AI and Personalized Cell Therapy Investment Opportunities
- Heartflow Financial Performance: Heartflow reported a revenue of $176 million for FY 2025, reflecting a 40% year-over-year increase despite a net loss of $116.8 million, with its core FFR CT Analysis product generating 98% of revenue, indicating strong market demand and growth potential.
- Iovance Revenue Growth: Iovance achieved a revenue of $263.5 million in FY 2025, marking a 60.6% increase year-over-year, although it recorded a net loss of approximately $391 million; the successful commercialization of its primary products Amtagvi and Proleukin highlights its strong potential in cancer treatment.
- Risk Analysis: Heartflow faces significant concentration risk due to reliance on a single product, alongside scrutiny from a U.S. Department of Justice investigation and potential Medicare reimbursement cuts, while Iovance contends with a $2.9 billion accumulated deficit and risks associated with its complex manufacturing processes.
- Valuation Comparison: Neither company is expected to be profitable in 2026, with Heartflow's price-to-sales ratio at 13.8 and Iovance at 5.3, suggesting that Iovance may offer a more attractive risk-adjusted opportunity for investors based on its lower valuation metrics.
See More
Investment Choices Between HeartFlow and NovoCure: Diagnostics vs. Therapeutics
- HeartFlow's Diagnostic Technology: HeartFlow employs AI for non-invasive diagnosis of coronary artery disease, achieving approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite reporting a net loss of $116.8 million, highlighting a tension between market expansion potential and profitability.
- Cancer Treatment Innovation: NovoCure's Tumor Treating Fields therapy generated about $655.4 million in revenue for FY 2025, an 8.3% increase, yet it also faced a net loss of nearly $136.2 million, indicating ongoing pressure from significant investments in its clinical pipeline.
- Risks and Challenges: HeartFlow's revenue is heavily concentrated, with 98% coming from its core diagnostic tool, and it is currently under a Civil Investigative Demand from the DOJ and facing patent litigation, which could impact future revenues; meanwhile, NovoCure's reliance on its Optune products exposes it to regulatory risks and collaboration risks with Zai Lab.
- Market Outlook Comparison: Although neither company is profitable, NovoCure's projected revenue of $704 million for FY 2026 significantly surpasses HeartFlow's $230 million, and its lower price-to-sales ratio presents a relative bargain, making NovoCure a more attractive option for long-term investors.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
